These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 21174558)

  • 21. Species-specific activity of glycolipid ligands for invariant NKT cells.
    Dangerfield EM; Cheng JM; Knight DA; Weinkove R; Dunbar PR; Hermans IF; Timmer MS; Stocker BL
    Chembiochem; 2012 Jun; 13(9):1349-56. PubMed ID: 22639457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interview: glycolipid antigen presentation by CD1d and the therapeutic potential of NKT cell activation.
    Kronenberg M
    J Vis Exp; 2007; (10):635. PubMed ID: 18989407
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective ability of mouse CD1 to present glycolipids: alpha-galactosylceramide specifically stimulates V alpha 14+ NK T lymphocytes.
    Burdin N; Brossay L; Koezuka Y; Smiley ST; Grusby MJ; Gui M; Taniguchi M; Hayakawa K; Kronenberg M
    J Immunol; 1998 Oct; 161(7):3271-81. PubMed ID: 9759842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined proinflammatory cytokine and cognate activation of invariant natural killer T cells enhances anti-DNA antibody responses.
    Sedimbi SK; Hägglöf T; Garimella MG; Wang S; Duhlin A; Coelho A; Ingelshed K; Mondoc E; Malin SG; Holmdahl R; Lane DP; Leadbetter EA; Karlsson MCI
    Proc Natl Acad Sci U S A; 2020 Apr; 117(16):9054-9063. PubMed ID: 32295878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of invariant natural killer T cells in immune regulation and as potential therapeutic targets in autoimmune disease.
    Van Kaer L
    Expert Rev Clin Immunol; 2006 Sep; 2(5):745-57. PubMed ID: 20477630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The specialized iNKT cell system recognizes glycolipid antigens and bridges the innate and acquired immune systems with potential applications for cancer therapy.
    Taniguchi M; Tashiro T; Dashtsoodol N; Hongo N; Watarai H
    Int Immunol; 2010 Jan; 22(1):1-6. PubMed ID: 19858073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Attenuation of invariant natural killer T-cell anergy induction through intradermal delivery of alpha-galactosylceramide.
    Bontkes HJ; Moreno M; Hangalapura B; Lindenberg JJ; de Groot J; Lougheed S; van der Vliet HJ; van den Eertwegh AJ; de Gruijl TD; von Blomberg BM; Scheper RJ
    Clin Immunol; 2010 Sep; 136(3):364-74. PubMed ID: 20570567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synergistic induction of adaptive antitumor immunity by codelivery of antigen with α-galactosylceramide on exosomes.
    Gehrmann U; Hiltbrunner S; Georgoudaki AM; Karlsson MC; Näslund TI; Gabrielsson S
    Cancer Res; 2013 Jul; 73(13):3865-76. PubMed ID: 23658368
    [TBL] [Abstract][Full Text] [Related]  

  • 29. alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles.
    Van Kaer L
    Nat Rev Immunol; 2005 Jan; 5(1):31-42. PubMed ID: 15630427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Invariant and noninvariant natural killer T cells exert opposite regulatory functions on the immune response during murine schistosomiasis.
    Mallevaey T; Fontaine J; Breuilh L; Paget C; Castro-Keller A; Vendeville C; Capron M; Leite-de-Moraes M; Trottein F; Faveeuw C
    Infect Immun; 2007 May; 75(5):2171-80. PubMed ID: 17353286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer.
    Motohashi S; Okamoto Y; Yoshino I; Nakayama T
    Clin Immunol; 2011 Aug; 140(2):167-76. PubMed ID: 21349771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bacterial CD1d-restricted glycolipids induce IL-10 production by human regulatory T cells upon cross-talk with invariant NKT cells.
    Venken K; Decruy T; Aspeslagh S; Van Calenbergh S; Lambrecht BN; Elewaut D
    J Immunol; 2013 Sep; 191(5):2174-83. PubMed ID: 23898038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 4"-O-Alkylated α-Galactosylceramide Analogues as iNKT-Cell Antigens: Synthetic, Biological, and Structural Studies.
    Janssens J; Bitra A; Wang J; Decruy T; Venken K; van der Eycken J; Elewaut D; Zajonc DM; van Calenbergh S
    ChemMedChem; 2019 Jan; 14(1):147-168. PubMed ID: 30556652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression.
    Stolk D; van der Vliet HJ; de Gruijl TD; van Kooyk Y; Exley MA
    Front Immunol; 2018; 9():1990. PubMed ID: 30298063
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical experience with α-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection.
    Schneiders FL; Scheper RJ; von Blomberg BM; Woltman AM; Janssen HL; van den Eertwegh AJ; Verheul HM; de Gruijl TD; van der Vliet HJ
    Clin Immunol; 2011 Aug; 140(2):130-41. PubMed ID: 21169066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glycolipid ligands of invariant natural killer T cells as vaccine adjuvants.
    Kim S; Lalani S; Parekh VV; Wu L; Van Kaer L
    Expert Rev Vaccines; 2008 Dec; 7(10):1519-32. PubMed ID: 19053208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cigarette smoke alters the invariant natural killer T cell function and may inhibit anti-tumor responses.
    Hogan AE; Corrigan MA; O'Reilly V; Gaoatswe G; O'Connell J; Doherty DG; Lynch L; O'Shea D
    Clin Immunol; 2011 Sep; 140(3):229-35. PubMed ID: 21684213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glycolipid activators of invariant NKT cells as vaccine adjuvants.
    Kharkwal SS; Arora P; Porcelli SA
    Immunogenetics; 2016 Aug; 68(8):597-610. PubMed ID: 27377623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glycolipids injected into the skin are presented to NKT cells in the draining lymph node independently of migratory skin dendritic cells.
    Tripp CH; Sparber F; Hermans IF; Romani N; Stoitzner P
    J Immunol; 2009 Jun; 182(12):7644-54. PubMed ID: 19494288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of marginal zone B lymphocytes in invariant NKT cell activation.
    Bialecki E; Paget C; Fontaine J; Capron M; Trottein F; Faveeuw C
    J Immunol; 2009 May; 182(10):6105-13. PubMed ID: 19414762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.